Anika Therapeutics Financial Statements (ANIK)
|
|
|
|
Report date
|
|
|
11.03.2022 |
16.03.2023 |
15.03.2024 |
17.03.2025 |
03.03.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
147.8 |
113.8 |
120.8 |
119.9 |
112.8 |
|
116.3 |
|
Operating Income, bln rub |
|
|
2.62 |
3.67 |
0.844 |
-5.10 |
-11.1 |
|
-12.3 |
|
EBITDA, bln rub |
? |
|
-4.16 |
18.2 |
15.1 |
3.02 |
-5.32 |
|
-6.63 |
|
Net profit, bln rub |
? |
|
4.13 |
-14.9 |
-82.7 |
-56.4 |
-10.9 |
|
-11.1 |
|
|
OCF, bln rub |
? |
|
8.40 |
4.41 |
-1.79 |
5.40 |
11.2 |
|
6.47 |
|
CAPEX, bln rub |
? |
|
5.14 |
7.49 |
5.43 |
7.73 |
6.83 |
|
5.43 |
|
FCF, bln rub |
? |
|
3.25 |
-3.08 |
-7.22 |
-2.33 |
4.36 |
|
1.04 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
80.3 |
69.6 |
81.7 |
81.1 |
74.9 |
|
80.4 |
|
Cost of production, bln rub |
|
|
64.9 |
40.6 |
38.3 |
43.9 |
49.0 |
|
48.1 |
|
R&D, bln rub |
|
|
27.3 |
18.3 |
21.8 |
25.5 |
25.8 |
|
26.4 |
|
Interest expenses, bln rub |
|
|
|
0.000 |
0.000 |
|
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
347.5 |
349.1 |
270.6 |
202.7 |
190.3 |
|
179.4 |
|
Net Assets, bln rub |
? |
|
287.1 |
285.6 |
212.3 |
154.0 |
143.5 |
|
133.9 |
|
Debt, bln rub |
|
|
21.0 |
30.9 |
27.7 |
25.9 |
24.2 |
|
25.7 |
|
Cash, bln rub |
|
|
94.4 |
86.3 |
68.7 |
55.6 |
57.5 |
|
41.0 |
|
Net debt, bln rub |
|
|
-73.4 |
-55.4 |
-41.0 |
-29.7 |
-33.3 |
|
-15.3 |
|
|
Ordinary share price, rub |
|
|
35.8 |
|
|
16.5 |
9.61 |
|
14.9 |
|
Number of ordinary shares, mln |
|
|
14.4 |
14.6 |
14.7 |
14.7 |
14.3 |
|
13.5 |
|
|
Market cap, bln rub |
|
|
516 |
0 |
0 |
242 |
138 |
|
202 |
|
EV, bln rub |
? |
|
443 |
-55 |
-41 |
213 |
105 |
|
187 |
|
Book value, bln rub |
|
|
197 |
204 |
202 |
144 |
134 |
|
124 |
|
|
EPS, rub |
? |
|
0.29 |
-1.02 |
-5.64 |
-3.83 |
-0.76 |
|
-0.82 |
|
FCF/share, rub |
|
|
0.23 |
-0.21 |
-0.49 |
-0.16 |
0.30 |
|
0.08 |
|
BV/share, rub |
|
|
13.7 |
14.0 |
13.8 |
9.81 |
9.33 |
|
9.19 |
|
|
EBITDA margin, % |
? |
|
-2.82% |
16.0% |
12.5% |
2.52% |
-4.72% |
|
-5.70% |
|
Net margin, % |
? |
|
2.80% |
-13.1% |
-68.4% |
-47.0% |
-9.64% |
|
-9.52% |
|
FCF yield, % |
? |
|
0.63% |
|
|
-0.96% |
3.17% |
|
0.51% |
|
ROE, % |
? |
|
1.44% |
-5.20% |
-38.9% |
-36.6% |
-7.58% |
|
-8.26% |
|
ROA, % |
? |
|
1.19% |
-4.26% |
-30.5% |
-27.8% |
-5.72% |
|
-6.17% |
|
|
P/E |
? |
|
124.8 |
0.00 |
0.00 |
-4.30 |
-12.7 |
|
-18.2 |
|
P/FCF |
|
|
158.6 |
0.00 |
0.00 |
-104.0 |
31.6 |
|
194.3 |
|
P/S |
? |
|
3.49 |
0.00 |
0.00 |
2.02 |
1.22 |
|
1.74 |
|
P/BV |
? |
|
2.62 |
0.00 |
0.00 |
1.68 |
1.03 |
|
1.62 |
|
EV/EBITDA |
? |
|
-106.3 |
-3.05 |
-2.72 |
70.4 |
-19.6 |
|
-28.1 |
|
Debt/EBITDA |
|
|
17.6 |
-3.05 |
-2.72 |
-9.83 |
6.25 |
|
2.31 |
|
|
R&D/CAPEX, % |
|
|
531.3% |
244.7% |
401.0% |
330.3% |
377.5% |
|
486.4% |
|
|
CAPEX/Revenue, % |
|
|
3.48% |
6.58% |
4.49% |
6.45% |
6.05% |
|
4.67% |
|
| Anika Therapeutics shareholders |
